Candidemia is common in extremely low birth weight infants and is associated with substantial mortality and morbidity. Treatment options have traditionally been limited to amphotericin B deoxycholate or fluconazole. We present a case of a premature infant with persistent candidemia despite antifungal treatment that responded to therapy with caspofungin, an echinocandin antifungal. The infant's Candida isolate developed resistance to azoles during fluconazole administration and also suffered from severe hypercalcemia during the initiation of caspofungin therapy.
Introduction
Candidemia is common in the neonatal intensive care unit. 1 Extremely premature infants are most at risk for infection. Clinicians are often faced with persistent Candida infections in this population despite antifungal therapy and optimal central catheter management. Caspofungin is a fungicidal antifungal that has seen limited use in the neonatal population owing to a paucity of data on pharmacokinetics and few reports of use in this population. We report the successful treatment of an infant with persistent candidemia using caspofungin.
Case report
The patient was an 810 g quadruplet male born via Caesarian-section at 25 weeks gestation. The patient received oral nystatin for fungal prophylaxis. The clinical course was remarkable for multiple complications including grade IV intraventricular hemorrhages, pneumothorax, patent ductus arteriosus requiring surgical ligation, spontaneous ileal perforation necessitating the creation of ostomies and necrotizing enterocolitis. Antimicrobial exposure preceding the fungal infection included 26 days of ampicillin, 32 days of gentamicin, 10 days of metronidazole, 15 days of vancomycin and 5 days of amphotericin B deoxycholate. The development of a conjugated hyperbilirubinemia on day of life (DOL) 80 prompted an abdominal ultrasound demonstrating debris within the right kidney consistent with candidiasis and a urine culture positive for Candida albicans. Two days later, blood cultures were positive for C. albicans; however, cerebrospinal fluid cultures were negative with unremarkable cell and chemistry parameters. Echocardiogram, head ultrasounds and ophthalmologic examinations were also unremarkable.
The infant was initially placed on amphotericin B deoxycholate, but was changed to amphotericin B lipid complex owing to substantially reduced urine output and elevated creatinine ( Figure 1 ). Despite the addition of fluconazole and removal of central venous catheters, blood cultures remained persistently positive with C. albicans for 41 days. Serial ultrasounds revealed increasing debris in both kidneys and dilation of the collecting system of the right kidney necessitating nephrostomy tube placement. After this procedure, the patient clinically deteriorated and required ionotropic support and high-frequency ventilation. At this point, the infant had received 30 days of fluconazole and 32 days of amphotericin B deoxycholate (1 mg/kg), amphotericin B lipid complex (5 mg/kg) or liposomal amphotericin B (7 mg/kg).
Caspofungin therapy was initiated with a loading dose of 100 mg/m 2 (8 mg/kg) followed by a maintenance dose of 70 mg/m 2 /day (6 mg/kg/day). The patient experienced dramatic clinical improvement, and renal ultrasounds demonstrated a decreasing amount of debris within the collecting system of the kidneys. Blood and urine cultures were negative 8 days after institution of caspofungin therapy.
On routine laboratory testing, the infant's serum calcium was found to be elevated at 16.8 mg/dl on day 14 of caspofungin therapy. The serum phosphorus and magnesium were also elevated at 9.3 and 3.6 mg/dl, respectively. The infant was tolerating small amounts of enteral feeds of Neocate, and no major changes to the parenteral nutrition composition had been made in the days before the episode of hypercalcemia. No etiology for these findings was determined; however, caspofungin therapy was discontinued for 72 h, and the laboratory values were normalized. Voriconazole therapy was begun during the interim, but in vitro susceptibility testing of the most recent C. albicans isolate demonstrated resistance to voriconazole as well as fluconazole (Table 1) . Caspofungin was restarted at a dose of 35 mg/m 2 /day (3 mg/kg). The patient's calcium levels remained normal throughout the additional 48 days of therapy, and the patient was discharged home on DOL 211.
Discussion
Caspofungin, an echinocandin, irreversibly inhibits 1,3 b-D glucan synthase in the fungal cell wall. 2 Lack of 1,3 b-D glucan decreases the integrity of the fungal cell wall leading to yeast cell lysis. Caspofungin is fungicidal in vitro for all medically important Candida species.
A study of 39 pediatric patients (ages 2-17 years) determined that weight-based dosing (1 mg/kg/day) yielded suboptimal serum levels. 3 A scheme based on body-surface area dosing (maintenance dose of 50 mg/m 2 /day) was found to better approximate levels of adults given 50 mg/day. Unfortunately, pharmacokinetic data for caspofungin in infants are nonexistent as of this writing.
Clinical experience with caspofungin as a therapeutic agent in infants is also limited. Odio et al. 4 reported 10 candidemic infants treated with caspofungin after failure of therapy with amphotericin B. The infants were given a dose of 1 mg/kg/day for 2 days followed by 2 mg/kg/day. One infant died of Klebsiella pneumoniae sepsis after 19 days of caspofungin therapy, but the remaining nine infants survived. A second report of 13 infants with persistent candidemia demonstrated sterilization of blood cultures in 11 infants given a 1 mg/kg/day dosing regimen of caspofungin. 5 However, only six of the infants survived. It is unclear if the doses utilized in those two previous reports were optimal, especially given the disparate survival results.
Hypercalcemia associated with caspofungin use has not been previously described, but has been noted in the setting of disseminated candidiasis and other infections, including coccidioidomycosis, histoplasmosis and pneumocystosis. 6 Hypercalcemia is thought to be caused by extrarenal 1a-hydroxylation of 25-hydoxy-vitamin D by cytokine-stimulated macrophages. Although no vitamin D levels or urine electrolytes were determined in our patient, parathyroid hormone levels were depressed (5 pg/ml). No adverse events were noted in the cohort of infants presented by Odio et al. 4 Natarajan et al. 5 observed thrombophlebitis in one patient, hypokalemia in two patients, elevated liver enzymes in four patients and isolated direct hyperbilirubinemia in one patient in their cohort of infants.
Administration of fluconazole leading to azole resistance has been noted in neonatal intensive care units, as occurred in our patient. However, we believe this is the first reported instance of cross-resistance to voriconazole in an infant. Voriconazole use is also limited in infants due to concerns with retinal side effects seen in older patients and the possible yet unknown interaction with retinopathy of prematurity. Although voriconazole has been shown to be active against Candida isolates such as C. glabrata and C. krusei that are often resistant to fluconazole, some authors caution its use in situations where fluconazole resistance is suspected. 7 This case illustrates the therapeutic potential of echinocandins for neonatal candidiasis. 4 However, understanding of echinocandin pharmacokinetics and safety in this patient group are required before widespread use. 
